The administration of ethinyl estradiol to 100 survivors of myocardial infarction resulted in uniform correction of the abnormal circulating lipid and lipoprotein concentrations. Gynecomastia and depression of libido were well tolerated by the patients but were not ameliorated by an This report, which elaborates this effect of the estrogenic hormones and describes the influences of androgens and progestins, is part of a comprehensive study of the hormonal factors which may be involved in the homeostasis of the circulating lipids and lipoproteins, and of lipid metabolism.
D URING the fourth and fifth decades of life, the clinical manifestations of coronary sclerosis are impressively more frequent in men than in women. So long as their reproductive physiology is maintained, women apparently enjoy some protection from the development of clinical coronary disease. There are abnormalities of the circulating lipids'-3 and lipoproteins4-7 in association with clinical coronary disease, and during the menstrual cycle there are cyclical variations in the circulating lipids and lipoproteins. It has been suggested that the physiologic depression at ovulation of plasma total cholesterol and the plasma total-cholesterol: phospholipid ratio (the C/P ratio) might be due to endogenous estrogen secretion. 8 (Scotland) . 82 This report, which elaborates this effect of the estrogenic hormones and describes the influences of androgens and progestins, is part of a comprehensive study of the hormonal factors which may be involved in the homeostasis of the circulating lipids and lipoproteins, and of lipid metabolism.
METHODS AND RESULTS
All the subjects were men whose ages ranged from 32 to 64 years, and all had electrocardiographic proof of myocardial infarction. A large majority of the men were in full employment and visited the Department of Cardiology in the Edinburgh Royal Infirmary during their working day. They attended at the same time at each visit and were not fasting or subject to any dietary restrictions, unless there was associated obesity. With the exception of the long-term ethinyl estradiol study, for which the selection of cases followed a separate pattern, all the subjects were hypercholesterolemic and at least three months had elapsed between the time of the infarct and the start of the investigation. Plasma total cholesterol was estimated by (table 1) .
(c) Long-Term Study. This investigation differed from the others in that the principal object was an attempt to assess the effect of ethinyl estradiol on the morbidity and mortality rates in men who were admitted to hospital following their first myocardial infarct; the results of this aspect of this longterm study will be reported in full when the series is larger and more time has elapsed. Between four and six weeks after discharge from hospital, alternate cases received either tablets containing 200 MAg. of ethinyl estradiol or identical inert tablets. In each group 25 men have been followed for 3 months, 20 men for 6 months, 16 men for 9 months, 10 men for 12 months and 6 men for 15 months. As the subjects were consecutive admissions, not all were hypercholesterolemic, although they all showed some abnormality of their circulating lipids or lipoproteins.
The results of this study are shown in figure 3. In the group receiving ethinyl estradiol, the plasma total cholesterol fell from 255 mg. per 100 cc. to 222 mg. per 100 cc. 15 months later, a fall of 13 
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The majority of the 100 men who have received ethinyl estradiol experienced gynecomastia, which at first caused some concern to a few but was generally very well tolerated. Depression or loss of libido was not uncommon, but caused acute distress in only one case. Nausea occurred occasionally and caused the withdrawal of the estrogen in two cases; these subjects were excluded from the studies. Angina occurred more readily and more severely in two men and ethinyl estradiol was withdrawn from them both, and they were also excluded from these studies. lesterol fell from 286 mg. per 100 cc. to 261 mg. per 100 cc. after 14 days, a fall of 9 per cent, and the total-cholesterol:phospholipid ratio remained constant at 0.94. The alpha:beta lipoprotein ratio fell from 13:87 to 11:89 (table 1) . Despite the lack of response to estrone while it was being administered, a slight rebound occurred in the plasma total cholesterol which rose to 300 mg. per 100 cc. two weeks after estrone was withdrawn; the total-cholesterol: phospholipid ratio rose to 1.03 at that time, but there was no rebound in the alpha:beta lipoprotein ratio. (3) Hexestrol Six men received 60 mg. of hexoestrol (British Drug Houses) orally each day for 14 days. The results of this study are shown in figure 8 . The plasma total cholesterol fell from 272 mg. per 100 cc. to 247 mg. per 100 cc. after 14 days, a fall of 9 per cent (p > 0.5), and the total-cholesterol: phospholipid ratio fell from 1.01 to 0.85, a fall of 16 per cent (p < 0.05). figure 13 . The plasma total cholesterol and the total-cholesterol: phospholipid ratio did not undergo any significant change during or after the course. Similarly the alpha: beta lipoprotein ratio failed to show significant change (table 1). The packed cell volumes and the weights of these men did not alter.
When the concentration of cholesterol oii the alpha and beta lipoprotein fractions was expressed in mg. per 100 cc., the cholesterol on the beta lipoprotein fraction decreased absolutely and the cholesterol on the alpha lipoprotein fraction increased absolutely during the administration of ethinyl estradiol and, conversely, during the administration of methyl testosterone.
Discussiox-
There can be no doubt from our studies on 100 survivors of myocardial infarction that ethinyl estradiol caused uniform depression of the plasma total cholesterol, the total-cholesterol:phospholipid ratio and the concentration of cholesterol attached to the beta lipoprotein fraction, and therefore a rise in the serum alpha:beta ratio. These results confirm our previous observation" and those of Barr, Russ and Eder,10 Barr1' 1 ' and Steiner, Payson and Kendall.'4 The percentage fall in the totalcholesterol: phospholipid ratio was greater than the percentage fall in the plasma total cholesterol whether ethinyl estradiol was administered at a low dose over a long period, in increasing doses over a moderate period or at a high dose over a short period. In these studies, ethinyl estradiol caused elevation of the plasma phospholipids as well as depression of the total cholesterol. This observation agrees with the findings of Eilert,"8 Barr and associates,"
Barr11" 1 and Steiner and co-workers'4 and contrasts with our previous observation that the phospholipids remained more or less (oiistant." There was no significant alteration in body weight or in plasma volume, as judged by hematocrit determinations, in these men who were not subject to any dietetic restrictions. There was no significant difference in the degree or rate of the depression of plasma total cholesterol and the total cholesterol-phospho-lipid ratio at the end of six weeks whether ethinyl estradiol was administered at a level of 1 mg. daily, at a level of 200 Mg. daily or was increased gradually from 200 Mg. to 1 mg. daily. This comparative study of the dosage of ethinyl estradiol was not possible beyond six weeks as some of the men who received 1 mg. of ethinyl estradiol complained of side effects, but it suggests that a dose larger than 200 Mg. daily is not more effective in depressing the circulating lipids and may even be a disadvantage as side effects are more readily encountered. Generally, the higher the plasma total cholesterol, the total-cholesterol: phospholipid ratio and the concentration of cholesterol attached to the beta lipoprotein fraction the greater the response to the administration of ethinyl estradiol.
Ethinyl estradiol was the only estrogen preparation which produced highly significant depression of the circulating lipids and of the concentration of cholesterol attached to the beta lipoprotein fraction although hexestrol and estradiol administration resulted in a similar trend. The two principal side effects of ethinyl estradiol administration, gynecomastia and depression of libido, were remarkably well tolerated and were not regarded as major obstacles to the administration of estrogens to men. However, an attempt was made to minimize these side effects by the combination of an androgen or a progestin with ethinyl estradiol.
The simultaneous administration of methyl testosterone and ethinyl estradiol resulted in partial inhibition of the depressant action of the estrogen on the circulating lipids and lipoproteins. This inhibition was apparent when ethinyl estradiol was introduced in the course of the administration of methyl testosterone and in the converse study. Moreover, continued administration of methyl testosterone following withdrawal of ethinyl estradiol resulted in further elevation of the plasma total cholesterol and the total-cholesterol: phospholipid ratio and this elevation may partly be due to the rebound sometimes seen after withdrawal of ethinyl estradiol. When methyl testosterone was given alone there was no significant elevation in the plasma total-cholesterol or the total-cholesterol: phospholipid ratio but the alpha: beta lipoprotein ratio fell significantly. The effect of methyl testosterone on the plasma total cholesterol and on the total cholesterol: phospholipid ratio was more striking when ethinyl estradiol had been administered and its action was being antagonized. These observations are in agreement with those of Barr."" 13 In our experience, methyl testosterone failed to ameliorate any of the side effects produced by ethinyl estradiol. The development of clinical jaundice in four men is in accord with the experiences of Werner who attributes to methyl testosterone a hepatotoxic action manifested by biliary stasis.'9' 20 Progesterone administered intramuscularly failed to elicit any response in the circulating lipids and lipoproteins, although a progesterone analogue (ethinyl testosterone) administered sublingually produced some depression of the plasma total cholesterol and the plasma phospholipids. In our experience the administration of this progesterone analogue also failed to ameliorate any of the side effects produced by ethinyl estradiol.
The mechanism by which ethinyl estradiol ameliorates the abnormal circulating lipid and lipoprotein patterns in coronary disease is at present obscure. The liver is probably the principal site of biosynthesis and catabolism of the circulating cholesterol, the quantity of which is largely dependent on the net result of these opposing dynamic processes; either or both of these processes may be influenced directly or indirectly by ethinyl estradiol. It 
SEX HORMIONES AND CIRCULATING LIPIDS AND LIPOPROTEINS
There is considerable evidence that human coronary atherogenesis is influenced by sex. There is a striking sex difference in the incidence of the clinical manifestations of coronary sclerosis during the fourth and fifth decades. An analysis of 1000 consecutive patients with clinical coronary disease indicated that it was 19 times more common in men than in women under the age of 35 and 15 times more common under the age of 40.27 Young men have lower alpha: beta lipoprotein ratios5 22-24 and a higher concentration of Sf 12-20 low density lipoproteins25 than young women; it is probable that this sex difference in lipoprotein concentrations depends to some extent on cyclical variations which occur during the menstrual cycle and may be related to endogenous estrogen secretion. 8' 9 Morphologic studies indicate that the physical characteristics of the very masculine and robust male are just those most commonly found to excess in subjects of coronary disease. 26 The estrogenic and androgenie sex hormones seem to be mutually antagonistic so far as the circulating lipids and lipoproteins are concerned and the estrogenandrogen balance may be of considerable importance in the development of clinical coronary disease. Whether alteration of this balance by estrogens will result in retardation of the atherosclerotic process and, if so, whether belated control of this process is of any value once it has become manifest clinically, can only be determined by further investigation and assessment in terms of morbidity and mortality.
SUMMARY
(1) The administration of ethinyl estradiol to men with myocardial infarction decreased the plasma total cholesterol, elevated the plasma phospholipids thereby depressing the total cholesterol-phospholipid ratio and decreased the concentration of cholesterol attached to the beta lipoprotein fraction.
(2) A daily dose of more than 200 jig. of ethinyl estradiol was no more effective in its influence on the circulating lipids and lipoproteins and was regarded as a disadvantage, as it was more readily associated with feminizing side effects.
(3) Hexestrol and estradiol had a similar but less marked effect.
(4) Ethinyl estradiol and methyl testosterone had a mutually antagonistic action on the circulating lipids and lipoproteins.
(5) Progesterone had no significant action on the circulating lipids and lipoproteins.
(6) Methyl testosterone and ethinyl testosterone failed to relieve the side effects of ethinyl estradiol administration.
(7) The efficacy of ethinyl estradiol administration in coronary disease must await assessment in terms of morbidity and mortality rates, rather than in its ability to correct the abnormal circulating lipid and lipoprotein concentrations. ACKNOWLEDGMENT 
